Would male hormonal contraceptives affect cardiovascular risk

被引:8
|
作者
Zitzmann, Michael [1 ]
机构
[1] Univ Clin Muenster, Ctr Androl & Reprod Med, Munster, Germany
关键词
cardiovascular risk; male contraception; progestins; testosterone; TESTOSTERONE UNDECANOATE; NORETHISTERONE ENANTHATE; COMBINATION; LEVONORGESTREL; SUPPRESSION; SPERMATOGENESIS; PROGESTINS; EFFICACY; EXTENT; TRIAL;
D O I
10.4103/aja.aja_2_18
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
The aim of hormonal male contraception is to prevent unintended pregnancies by suppressing spermatogenesis. Hormonal male contraception is based on the principle that exogenous administration of androgens and other hormones such as progestins suppress circulating gonadotropin concentrations, decreasing testicular Leydig cell and Sertoli cell activity and spermatogenesis. In order to achieve more complete suppression of circulating gonadotropins and spermatogenesis, a progestin has been added testosterone to the most recent efficacy trials of hormonal male contraceptives. This review focusses on the potential effects of male hormonal contraceptives on cardiovascular risk factors, lipids and body composition, mainly in the target group of younger to middle-aged men. Present data suggest that hormonal male contraception can be reasonably regarded as safe in terms of cardiovascular risk. However, as all trials have been relatively short (< 3 years), a final statement regarding the cardiovascular safety of hormonal male contraception, especially in long-term use, cannot be made. Older men with at high risk of cardiovascular event might not be good candidates for hormonal male contraception. The potential adverse effects of hormonal contraceptives on cardiovascular risk appear to depend greatly on the choice of the progestin in regimens for hormonal male contraceptives. In the development of prospective hormonal male contraception, data on longer-term cardiovascular safety will be essential.
引用
下载
收藏
页码:145 / 148
页数:4
相关论文
共 50 条
  • [1] Cardiovascular risk of hormonal contraceptives - an update
    Dinger, J.
    GYNAKOLOGE, 2015, 48 (09): : 643 - 650
  • [2] Hormonal Male Contraceptives: A Review
    Gunardi, Eka Rusdianto
    Handoko, Yohanes
    Jamtani, Mona
    ADVANCED SCIENCE LETTERS, 2018, 24 (09) : 6728 - 6734
  • [3] Cardiovascular Risks of Hormonal Contraceptives
    Petitti D.B.
    Current Cardiovascular Risk Reports, 2013, 7 (3) : 190 - 195
  • [4] Update on the development of male hormonal contraceptives
    Anawalt, Bradley D.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (04) : 318 - 323
  • [5] PROSPECTS FOR NEW HORMONAL MALE CONTRACEPTIVES
    CUMMINGS, DE
    BREMNER, WJ
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1994, 23 (04) : 893 - 922
  • [6] CARDIOVASCULAR-DISEASES AND HORMONAL CONTRACEPTIVES
    MEINEL, H
    ZEITSCHRIFT FUR KLINISCHE MEDIZIN-ZKM, 1987, 42 (04): : 310 - 310
  • [7] Hormonal Contraceptives and the Risk of Endometriosis
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07) : 594 - 594
  • [8] No Evidence That Hormonal Contraceptives Affect Chemosensory Perception
    Schaefer, Martin
    Iravani, Behzad
    Arshamian, Artin
    Lundstrom, Johan N.
    I-PERCEPTION, 2021, 12 (01):
  • [9] Oral hormonal contraceptives and cardiovascular risks in females
    Bhullar, Sukhwinder K.
    Rabinovich-Nikitin, Inna
    Kirshenbaum, Lorrie A.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024,
  • [10] Hormonal Contraceptives and the Risk of Venous Thrombosis
    Khialani, Deeksha
    Rosendaal, Frits
    Vlieg, Astrid van Hylckama
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2020, 46 (08): : 865 - 871